Observational studies leverage machine learning to create Mind.PxTM, a test that prospectively predicts biologic class response for individual psoriasis patients with high Positive Predictive Values (PPV)
SAN DIEGO, CA – November 16, 2021 – Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, has announced the publication of data and positive results from the observational STAMP-1 and STAMP-2 studies. These studies combined baseline dermal genetic testing using the Mind.Px™ platform to capture and analyze the whole transcriptome combined with proprietary artificial intelligence bioinformatics to develop predictive algorithms.
In 2019, the American Academy of Dermatology and the National Psoriasis Foundation published joint guidelines addressing care for the management and…